Feed CLYYF
CL
Celyad Oncology S.A. CLYYF · OTC
$0.28 +0.00% (+$0.00)
Depth
- Market cap
- 11.8M €
- Enterprise value
- 11.7M €
- P/E
- 3.6x
- Forward P/E
- -
- PEG
- -
- P/S
- 1,692.1x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -334.9%
- Gross margin
- 29,807.2%
- Net margin
- 47,201.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.21
- Free float
- 93.9%
Sector
Healthcare
Industry
Biotechnology
CEO
Michel E. J. Lussier
Employees
17
Headquarters
Mont-Saint-Guibert
Valuation
Is today's price reasonable?
- What speaks for it: You pay 3.6 EUR for 1 EUR of yearly profit, little for its sector.
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 EUR of revenue, 47,202 EUR is left as net profit.
- What to watch: It reports a profit, yet spends more cash than it brings in.
- What to watch: Its last loss-making year was 2 years ago.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: 120.8K € against 25.0K €.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number